Abstract
A novel protocol for the semi-synthesis of docetaxel was achieved in four steps from 10-deacetyl baccatin III with an overall yield of 50%. The key step is the selective protection of the C(7) and C(10) hydroxyl groups of 10- deacetyl baccatin III, utilizing benzyl chloromate as a selective protecting reagent, which are capable of being conveniently removed by Pd/C under hydrogen atmosphere.
Keywords: Docetaxel, semi-synthesis, 10-DAB III, benzyl chloromate
Letters in Organic Chemistry
Title: A Mild and Convenient Semi-Synthesis of Docetaxel from 10-Deacetyl Baccatin III
Volume: 7 Issue: 6
Author(s): Hui Zhou, Dahai Chen, Hongwei Gao and Qingeng Li
Affiliation:
Keywords: Docetaxel, semi-synthesis, 10-DAB III, benzyl chloromate
Abstract: A novel protocol for the semi-synthesis of docetaxel was achieved in four steps from 10-deacetyl baccatin III with an overall yield of 50%. The key step is the selective protection of the C(7) and C(10) hydroxyl groups of 10- deacetyl baccatin III, utilizing benzyl chloromate as a selective protecting reagent, which are capable of being conveniently removed by Pd/C under hydrogen atmosphere.
Export Options
About this article
Cite this article as:
Zhou Hui, Chen Dahai, Gao Hongwei and Li Qingeng, A Mild and Convenient Semi-Synthesis of Docetaxel from 10-Deacetyl Baccatin III, Letters in Organic Chemistry 2010; 7 (6) . https://dx.doi.org/10.2174/157017810791824892
DOI https://dx.doi.org/10.2174/157017810791824892 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances
Central Nervous System Agents in Medicinal Chemistry Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy MicroRNA in the Pathogenesis and Prognosis of Esophageal Cancer
Current Pharmaceutical Design Calcium-suppressed Technique in Dual-layer Detector Computed Tomography to Evaluate Knee Articular Cartilage
Current Medical Imaging Neuroprotective Therapies for Alzheimers Disease
Current Pharmaceutical Design Copper Complexes of 8-Aminoquinoline and Uracils as Novel Aromatase Inhibitors
Letters in Drug Design & Discovery When BMP Signalling Goes Wrong: The Intracellular and Molecular Mechanisms of BMP Signalling in Cancer
Current Signal Transduction Therapy Withdrawal Notice: Recent Developments in Anti-Cancer Activity of Compounds Containing the Thioether Group
Anti-Cancer Agents in Medicinal Chemistry Heterogeneity in the Pathology and Molecular Biology of Breast Cancer
Current Genomics Melanocortin-4 Receptor Antagonists as Potential Therapeutics in the Treatment of Cachexia
Current Topics in Medicinal Chemistry The Complexity of DEK Signaling in Cancer Progression
Current Cancer Drug Targets The Molecular Basis of Herpesviruses as Oncolytic Agents
Current Pharmaceutical Biotechnology Chalcones in Cancer: Understanding their Role in Terms of QSAR
Current Medicinal Chemistry May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials
Anti-Cancer Agents in Medicinal Chemistry Synthesis, Antioxidant and Anti-inflammatoy Effects of Antioxidant Acid Amides with GABA and N-Acyl-pyrrolidin-2-ones
Current Chemical Biology Occurrence, Structure Elucidation, Biosynthesis, Functions and Synthesis of Sphingadienes
Mini-Reviews in Organic Chemistry Efficacy of Therapy with c-Met/HGF Inhibitors in Solid Tumors: A Systematic Review Based on 24 Clinical Trials
Clinical Cancer Drugs Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Combination of Anti-EGFR Drugs with Anti-Angiogenic or Other Signal Transduction Inhibitors as a Rational Approach to Cancer Therapy
Current Cancer Therapy Reviews